JP7532009B2 - がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 - Google Patents

がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 Download PDF

Info

Publication number
JP7532009B2
JP7532009B2 JP2018553360A JP2018553360A JP7532009B2 JP 7532009 B2 JP7532009 B2 JP 7532009B2 JP 2018553360 A JP2018553360 A JP 2018553360A JP 2018553360 A JP2018553360 A JP 2018553360A JP 7532009 B2 JP7532009 B2 JP 7532009B2
Authority
JP
Japan
Prior art keywords
dose
antibody
cancer
hu5f9
priming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018553360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515899A5 (OSRAM
JP2019515899A (ja
Inventor
エル． ワイスマン，アービング
ピー． チャオ，マーク
マジェティ，ラビンドラ
リュウ，ジー
フォルクマー，ジェンス－ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2019515899A publication Critical patent/JP2019515899A/ja
Publication of JP2019515899A5 publication Critical patent/JP2019515899A5/ja
Priority to JP2022140214A priority Critical patent/JP7442591B2/ja
Priority to JP2024023723A priority patent/JP2024059764A/ja
Application granted granted Critical
Publication of JP7532009B2 publication Critical patent/JP7532009B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018553360A 2016-04-15 2017-04-14 がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 Active JP7532009B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022140214A JP7442591B2 (ja) 2016-04-15 2022-09-02 がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法
JP2024023723A JP2024059764A (ja) 2016-04-15 2024-02-20 がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662323330P 2016-04-15 2016-04-15
US62/323,330 2016-04-15
US201662427679P 2016-11-29 2016-11-29
US62/427,679 2016-11-29
PCT/US2017/027662 WO2017181033A1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022140214A Division JP7442591B2 (ja) 2016-04-15 2022-09-02 がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法

Publications (3)

Publication Number Publication Date
JP2019515899A JP2019515899A (ja) 2019-06-13
JP2019515899A5 JP2019515899A5 (OSRAM) 2020-05-14
JP7532009B2 true JP7532009B2 (ja) 2024-08-13

Family

ID=60042716

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018553360A Active JP7532009B2 (ja) 2016-04-15 2017-04-14 がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法
JP2022140214A Active JP7442591B2 (ja) 2016-04-15 2022-09-02 がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法
JP2024023723A Pending JP2024059764A (ja) 2016-04-15 2024-02-20 がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022140214A Active JP7442591B2 (ja) 2016-04-15 2022-09-02 がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法
JP2024023723A Pending JP2024059764A (ja) 2016-04-15 2024-02-20 がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法

Country Status (12)

Country Link
US (3) US11472878B2 (OSRAM)
EP (3) EP3442578B1 (OSRAM)
JP (3) JP7532009B2 (OSRAM)
KR (3) KR20240016445A (OSRAM)
CN (3) CN115350276A (OSRAM)
AU (2) AU2017250809B2 (OSRAM)
CA (1) CA3019676A1 (OSRAM)
ES (1) ES2909835T3 (OSRAM)
PL (1) PL3442578T3 (OSRAM)
PT (1) PT3442578T (OSRAM)
SI (1) SI3442578T1 (OSRAM)
WO (1) WO2017181033A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081898A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
CN111247172B (zh) 2017-10-18 2023-11-14 四十七公司 基于抗cd47剂的卵巢癌疗法
EP4129336B1 (en) 2018-02-12 2025-05-07 Forty Seven, LLC Anti-cd47 agent-based treatment of cd20-positive cancer
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
WO2020009725A1 (en) * 2018-07-05 2020-01-09 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
MY205933A (en) 2018-09-27 2024-11-21 Celgene Corp Sirp-alpha binding proteins and methods of use thereof
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
PL3817773T3 (pl) 2018-11-26 2024-10-28 Forty Seven, Inc. Humanizowane przeciwciała przeciwko c-kit
KR20210094609A (ko) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
KR20220113353A (ko) 2019-09-18 2022-08-12 람캅 바이오 알파 에이지 Ceacam5 및 cd3에 대한 이중특이적 항체
US11702474B2 (en) 2019-12-17 2023-07-18 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
US20230081265A1 (en) * 2020-04-06 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Antibody formulation
WO2022076928A1 (en) * 2020-10-09 2022-04-14 Sana Biotechnology, Inc. METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPα BLOCKADE AGENT
US12071481B2 (en) 2020-12-23 2024-08-27 D-10 Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
EP4274853A4 (en) * 2021-01-05 2024-12-04 National Institute Of Biological Sciences, Beijing BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47
WO2023002415A2 (en) * 2021-07-20 2023-01-26 Magenta Therapeutics, Inc. Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016507555A (ja) 2013-02-06 2016-03-10 インヒブルクス エルピー 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3056515T4 (da) 2008-01-15 2025-10-20 Univ Leland Stanford Junior Fremgangsmåde til at manipulere fagocytose medieret af cd47
CA2714006A1 (en) * 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
ES2616010T3 (es) * 2010-05-14 2017-06-09 The Board Of Trustees Of The Leland Stanford Junior University Anticuerpos monoclonales humanizados y quiméricos a CD47
CN104136037B (zh) 2012-01-17 2018-02-23 小利兰·斯坦福大学托管委员会 高亲和力SIRP‑α试剂
HRP20191500T1 (hr) 2012-02-06 2019-11-29 Inhibrx Inc Protutijela protiv cd47 i postupci njihove upotrebe
AU2014238105B2 (en) * 2013-03-15 2018-11-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-CD47 agents
RU2015145610A (ru) 2013-03-27 2017-05-04 Дженентек, Инк. Применение биомаркеров для оценки лечения желудочно-кишечных воспалительных расстройств антагонистами бета7 интегрина
ES2898627T3 (es) 2013-04-29 2022-03-08 Univ Leland Stanford Junior Uso de agentes anti-CD47 para mejorar la inmunización
WO2015050983A1 (en) 2013-10-01 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules
CN106456748A (zh) * 2014-01-08 2017-02-22 小利兰·斯坦福大学托管委员会 小细胞肺癌的靶向疗法
CN108025060A (zh) * 2014-06-08 2018-05-11 瑞美德生物医药科技有限公司 使用胰高血糖素受体拮抗性抗体治疗1型糖尿病的方法
WO2016028810A1 (en) * 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
EP3204420B1 (en) * 2014-10-10 2020-09-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods to eliminate cancer stem cells by targeting cd47
US20230081265A1 (en) * 2020-04-06 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Antibody formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016507555A (ja) 2013-02-06 2016-03-10 インヒブルクス エルピー 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ＰＬＯＳ ＯＮＥ ２０１５ ＤＯＩ：１０ １３７１／ｊｏｕｒｎａｌ．ｐｏｎｅ．０１３７３４５

Also Published As

Publication number Publication date
JP7442591B2 (ja) 2024-03-04
AU2017250809B2 (en) 2024-02-29
ES2909835T3 (es) 2022-05-10
EP3442578B1 (en) 2022-02-09
KR102505253B1 (ko) 2023-03-02
KR20180134367A (ko) 2018-12-18
US20230406923A1 (en) 2023-12-21
US11472878B2 (en) 2022-10-18
KR20240016445A (ko) 2024-02-06
CN117695387A (zh) 2024-03-15
US20230068235A1 (en) 2023-03-02
AU2024203396A1 (en) 2024-06-06
CN109152837A (zh) 2019-01-04
JP2019515899A (ja) 2019-06-13
CN115350276A (zh) 2022-11-18
JP2022172278A (ja) 2022-11-15
EP3442578A1 (en) 2019-02-20
EP3442578A4 (en) 2019-04-10
SI3442578T1 (sl) 2022-05-31
KR20230035435A (ko) 2023-03-13
JP2024059764A (ja) 2024-05-01
US20190106491A1 (en) 2019-04-11
AU2017250809A1 (en) 2018-10-25
CA3019676A1 (en) 2017-10-19
EP4074339A1 (en) 2022-10-19
PT3442578T (pt) 2022-05-19
WO2017181033A1 (en) 2017-10-19
PL3442578T3 (pl) 2022-06-20
US11718670B2 (en) 2023-08-08
EP4349412A3 (en) 2024-06-12
EP4349412A2 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
JP7532009B2 (ja) がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法
US20210277115A1 (en) Targeted therapy for small cell lung cancer
US10301387B2 (en) Methods for achieving therapeutically effective doses of anti-CD47 agents
JP7343528B2 (ja) 抗ｃｄ４７抗体及び抗ｃｄ２０抗体を使用する抗がんレジメン
JP7308191B2 (ja) 抗ｃｄ４７剤ベースの卵巣癌療法
HK40080891A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40107887A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40082292A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
WO2023185720A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
HK40029258A (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220902

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220902

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220922

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220927

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221028

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240731

R150 Certificate of patent or registration of utility model

Ref document number: 7532009

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150